Efficacy of Ipragliflozin Compared With Sitagliptin in Uncontrolled Type 2 Diabetes With Sulfonylurea and Metformin

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 170 participants.

Also called NCT03076112

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 170 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03076112
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03076112. Randomized; no masking; primary purpose treatment. Start 2017-04-25 (actual); primary completion 2022-06-30 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy of Ipragliflozin Compared With Sitagliptin in Uncontrolled Type 2 Diabetes With Sulfonylurea and Metformin
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
Ipragliflozin
Intervention (Drug)
Sitagliptin
Lead sponsor
Seoul National University Bundang Hospital (class: other)
Collaborator
Astellas Pharma Korea, Inc. (class: industry)

Record details

Record id
cardio:ct-nct03076112
Content hash
774040a346b7abbc011cceae53baa64d20489cfafcc542bab15c791f9d791469